New Quadrivalent Influenza Vaccine Demonstrates Benefits for Older Adults in Phase 3 Study

CSL Seqirus announced the publication of pivotal Phase 3 study results in The Lancet Infectious Diseases for its MF59®-adjuvanted cell-based higher-dose quadrivalent influenza vaccine (aQIVc). The study confirms the vaccine's benefits, combining three proven approaches to enhance protection against influenza for older adults. This represents an important advancement in influenza prevention for this demographic, who are particularly vulnerable to severe outcomes.